Live
- RBI issues alert against prepaid payment instruments by illegal entities
- Hackers attacked Indian firms on average 2,444 times per week in last 6 months: Report
- US election outcome not to change direction of South Korea-US alliance: Seoul envoy
- 'Manipur Super 50' scores big in providing opportunities to the state's youth
- L&T Technology Services logs Rs 1,304 crore in net profit in FY24
- Rajya Sainik Board-Kolkata empowers deceased veteran's daughter with mobility
- BJP complains to ECI against Abhishek Banerjee for 'abusive' remarks against party candidate
- IPL 2024: RCB elect to bat first against in-form Sunrisers
- Selectors likely to name squad for T20 World Cup this weekend, say BCCI sources
- 'Democracy is crying', Mamata Banerjee sharpens attack against HC ruling in school jobs case
Aurobindo gets observations from FDA for Hyderabad facility
Highlights
Aurobindo Pharma Ltd on Wednesday said that it has received an establishment inspection report from the US health regulator with Voluntary Action Initiated (VAl) status for its Unit VIII manufacturing facility in Hyderabad.
Hyderabad: Aurobindo Pharma Ltd on Wednesday said that it has received an establishment inspection report from the US health regulator with Voluntary Action Initiated (VAl) status for its Unit VIII manufacturing facility in Hyderabad.
"Further to our intimation dated November 6, 2019 with regard to the USFDA inspection of Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad, we would like to inform that the company has received the Establishment Inspection Report (EIR) with VAl status from the USFDA," the drug firm said.
USFDA issues an EIR to the company when an inspection is satisfactorily closed.
Next Story
ADVERTISEMENT
